Unknown

Dataset Information

0

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.


ABSTRACT: BACKGROUND:Pembrolizumab (PEMBRO) and ipilimumab?+?nivolumab (IPI?+?NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice. METHODS:A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI?+?NIVO between June 2017 and March 2018. Endpoints included the QLQ-C30 global health score (GHS) and EuroQol visual analog scale (EQ-VAS) scores. Mean changes were compared using repeated measures mixed-effects models and are presented covariate adjusted. RESULTS:225 PEMBRO and 187 IPI?+?NIVO patients were enrolled. From baseline through week 24, PEMBRO was associated with 3.2 mean GHS score increase (95% CI 0.5, 5.9; p?=?.02), while no change was observed with IPI?+?NIVO; 0.2 (95% CI - 2.6, 3.0; p?=?0.87). Among objective treatment-responders, GHS scores associated with PEMBRO increased 6.0 (95% CI 3.1, 8.8; p?

SUBMITTER: Joseph RW 

PROVIDER: S-EPMC7561540 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.

Joseph Richard W RW   Liu Frank Xiaoqing FX   Shillington Alicia C AC   Macahilig Cynthia P CP   Diede Scott J SJ   Dave Vaidehi V   Harshaw Qing Q   Saretsky Todd L TL   Pickard Alan Simon AS  

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20200513 10


<h4>Background</h4>Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice.<h4>Methods</h4>A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI + NIVO between June 2017 and March 2018. Endpoints included the QL  ...[more]

Similar Datasets

| S-EPMC9179437 | biostudies-literature
| S-EPMC4944869 | biostudies-literature
| S-EPMC9939122 | biostudies-literature
| S-EPMC7689762 | biostudies-literature
| S-EPMC7067409 | biostudies-literature
| S-EPMC5650125 | biostudies-literature
| S-EPMC10571707 | biostudies-literature
| S-EPMC10572061 | biostudies-literature
| S-EPMC6709121 | biostudies-literature
| S-EPMC5912975 | biostudies-literature